Navigation Links
Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
Date:2/25/2008

Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New

Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of high-priced branded agents will drive the systemic lupus erythematosus drug market to quadruple from approximately $325 million in 2006 to $1.4 billion in 2016.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the strongest drivers of market growth will be the formal approval of several therapies that target B cells, including Biogen Idec/Genentech/Zenyaku Kogyo's Rituxan/Roche's MabThera, as well as increased uptake of Roche/Aspreva Pharmaceuticals' branded immunosuppressant CellCept.

"The introduction of novel biologics, other targeted therapies, and immunosuppressants into the treatment regimens of patients with systemic lupus erythematosus will result in increased polypharmacy," said Amy Whiting, Ph.D., analyst at Decision Resources. "These agents will not replace existing therapies but rather be used in combination with existing drugs to provide more-effective and/or safer treatment."

The report finds that sales in the systemic lupus erythematosus drug market will experience a significant 24% annual increase between 2006 and 2011. Sales growth will then proceed at a slower pace of 9% annually from 2011 to 2016, owing to fewer new product launches, generic erosion of CellCept, and biogeneric erosion of Rituxan/MabThera.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disease characterized by a complex pathophysiology that results in widespread tissue damage of multiple organ systems. The disease affects more than 537,000 people in the United States, France, Germany, Italy
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. The Branded Pharmaceutical Association Comments on Hydrocodone
4. FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients
5. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
6. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
7. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
8. Allergic reactions to gadolinium-based contrast agents are rare, study finds
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Columbia, SC (PRWEB) September 02, 2014 The ... an outreach fair and public town hall meeting for Veterans ... be available at the outreach fair to provide Veterans with ... B. McMurry. “The town hall will provide a forum where ... our VA programs.” , The outreach fair will be held ...
(Date:9/2/2014)... early-stage breast cancer in California, the percentage undergoing a ... this procedure was not associated with a lower risk ... a study in the September 3 issue of ... the removal of one breast was associated with a ... in the study. , Randomized trials have demonstrated similar ...
(Date:9/2/2014)... Medex Analytic Services is delighted to announce the ... Fla. due to their greater than forecasted growth. , ... 2014 year by distinguishing Medex in the industry,” said ... level of service and professionalism in the delivery of ... has responded.” , The location of the new ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Two new ... One suggests that 6-year-olds who were breast-fed have a ... to bottle-fed infants, while the other finds a similar ... upholds the "many benefits of breast-feeding in the immediate ... Lenox Hill Hospital in New York City. She was ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... An Indian who moderates an Internet forum on HIV/AIDS ... 16th International AIDS Conference here scheduled from Aug 13. ... delegates to build support for eliminating disparities in access ... a conference co-chair and director of the McGill University ...
... prowess in adding muscle to existing blackcurrants with a view ... reflect in nutritive fruit beverages. The Scottish Crop Research Institute ... manufactured in the blackcurrant bushes, so that they could look ... study costing about ?1.2m will endeavor to enhance the quality ...
... cancer cells after breast cancer surgery may play a crucial ... a new study published// in the August 1, 2006, issue ... Physics, the official journal of ASTRO, the American Society for ... 213,000 American women will learn they have breast cancer. Many ...
... pregnancy counselling Medicare item number may well breach women's ... ,Available only to women who are uncertain about whether ... identification of women who talk to their GP about ... would put on the record the fact that a ...
... Low calorie foods that are high in nutrition may be the ... fear of piling calories//. After studying the dietary details of about ... vegetables and grains were likely to consume a larger quantity of ... despite consuming a lot of food, their calorie count was much ...
... paying their price by breaking bones and spraining ankles. ... off their high-heeled sandals, causing several injuries. ... emergency unit at University Hospital of Wales, Cardiff, pointed ... ,He advised women to wear shoes with ...
Cached Medicine News:Health News:Indian to Conduct Workshop at Global AIDS Meet 2Health News:Leftover Cancer Cells May Dictate Breast Cancer Relapse 2Health News:Doctors Warn on Pregnancy Counselling 2
(Date:9/2/2014)... September 2, 2014   ... atrial muestran agentes antitrombóticos no utilizados óptimamente para ... -- Las presentaciones de GARFIELD-AF en el ESC ... y los resultados de pacientes en riesgo de ...    Los datos de casi 12.500 ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... /PRNewswire-USNewswire/ – CoMeD – On Friday, July ... (UNEP) distributed a revised text for its comprehensive ... were gratified to see pharmaceuticals listed in "Annex C ... The Coalition for Mercury-free Drugs (CoMeD) ...
... Reportlinker.com announces that a new market ... Sustained Release Injectables: Evolving ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... to increase the duration of efficacy for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: